These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 456291)

  • 1. A new beta-lactam antibiotic: is it a major advance?
    Neu HC
    Drugs; 1979 Mar; 17(3):153-6. PubMed ID: 456291
    [No Abstract]   [Full Text] [Related]  

  • 2. [New beta-lactamases in enterobacteriaceae. The Danish Society of Clinical Microbiology].
    Hansen DS
    Ugeskr Laeger; 2006 Mar; 168(12):1228. PubMed ID: 16571319
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics.
    Thomson KS; Prevan AM; Sanders CC
    Curr Clin Top Infect Dis; 1996; 16():151-63. PubMed ID: 8714252
    [No Abstract]   [Full Text] [Related]  

  • 4. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment, with cefoxitin, of bacterial infections of different degrees of severity].
    Levi GC; Pasternak J; Amato Neto V; da Silva ML
    Rev Inst Med Trop Sao Paulo; 1979; 21(4):194-7. PubMed ID: 545641
    [No Abstract]   [Full Text] [Related]  

  • 6. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.
    Neu HC
    Annu Rev Pharmacol Toxicol; 1982; 22():599-642. PubMed ID: 6282190
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 8. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
    Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
    Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
    [No Abstract]   [Full Text] [Related]  

  • 9. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
    Harris PN; Tambyah PA; Paterson DL
    Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
    Heil EL; Johnson JK
    J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Part V. Other beta-lactam antimicrobials.
    Gibbs WJ; Cooper TW; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2007 Jan; 100(1):23-5. PubMed ID: 17378498
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of beta-lactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians.
    Kallen AJ; Beekmann SE; Limbago B; Lentnek AL; Polgreen PM; Patel J; Srinivasan A
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):316-9. PubMed ID: 21899980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial stewardship of β-lactams in intensive care units.
    Cotta MO; Roberts JA; Tabah A; Lipman J; Vogelaers D; Blot S
    Expert Rev Anti Infect Ther; 2014 May; 12(5):581-95. PubMed ID: 24655303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Lactam antibiotics in the newborn.
    Wilkinson PJ
    J Antimicrob Chemother; 1982 Feb; 9 Suppl B():21-9. PubMed ID: 7037735
    [No Abstract]   [Full Text] [Related]  

  • 15. beta-Lactams without a suicide inhibitor.
    Giamarellou H
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
    MacGowan A
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cephalosporin therapy in intraabdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin.
    Wilson SE
    J Chemother; 1989 Jul; 1(4 Suppl):820-2. PubMed ID: 16312655
    [No Abstract]   [Full Text] [Related]  

  • 18. Cephalosporin-induced leukopenia following rechallenge with cefoxitin.
    Whitman CB; Joseph JM; Sjoholm LO
    Ann Pharmacother; 2008 Sep; 42(9):1327-32. PubMed ID: 18648015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficiency of cefoxitin/cefepime combination against Enterobacteriaceae resistant to expanded-spectrum cephalosporins.
    Serres A; Gibold L; Dalmasso G; Robin F; Bonnet R; Delmas J
    Int J Antimicrob Agents; 2015 Jan; 45(1):86-7. PubMed ID: 25459401
    [No Abstract]   [Full Text] [Related]  

  • 20. [Uses in in ambulatory and stationary situations. Clinical indications for beta lactams].
    Lode HM
    Pharm Unserer Zeit; 2006; 35(5):428-31. PubMed ID: 17009787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.